HCV Notes: NICE Nod To Gilead's Epclusa; Achillion, AbbVie Data Updates
Executive Summary
The UK's health care cost-assessment body finds Gilead's newest combo, Epclusa, cost-effective in most HCV settings. J&J/Achillion now have 12-week SVR data for six-week treatment regimen, and AbbVie builds support for an eight-week regimen for Viekirax.